Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size

Abstract Introduction Cystic renal cell carcinoma (cystic RCC) is thought to carry an improved prognosis relative to clear cell RCC (CCRCC); however, this is based on small case series. We used a population-based tumor registry to compare clinicopathologic features and cancer-specific mortality (CSM...

Full description

Saved in:
Bibliographic Details
Published in:Urologic oncology 2015-12, Vol.33 (12), p.505.e9-505.e13
Main Authors: Winters, Brian R., M.D, Gore, John L., M.D., M.S, Holt, Sarah K., Ph.D, Harper, Jonathan D., M.D, Lin, Daniel W., M.D, Wright, Jonathan L., M.D., M.S
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Carcinoma, Renal Cell - diagnosis
Carcinoma, Renal Cell - mortality
Carcinoma, Renal Cell - pathology
Clear cell RCC
Cystic RCC
Female
Humans
Male
Middle Aged
Neoplasm Staging
Prognosis
Renal cell carcinoma
Survival
Survival Analysis
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c592t-79146344cd2e57ba28d6c1d57cd8dac49218345158d1cca7bc18d5d3cc913d5d3
cites cdi_FETCH-LOGICAL-c592t-79146344cd2e57ba28d6c1d57cd8dac49218345158d1cca7bc18d5d3cc913d5d3
container_end_page 505.e13
container_issue 12
container_start_page 505.e9
container_title Urologic oncology
container_volume 33
creator Winters, Brian R., M.D
Gore, John L., M.D., M.S
Holt, Sarah K., Ph.D
Harper, Jonathan D., M.D
Lin, Daniel W., M.D
Wright, Jonathan L., M.D., M.S
description Abstract Introduction Cystic renal cell carcinoma (cystic RCC) is thought to carry an improved prognosis relative to clear cell RCC (CCRCC); however, this is based on small case series. We used a population-based tumor registry to compare clinicopathologic features and cancer-specific mortality (CSM) of cystic RCC with those of CCRCC. Materials and methods The Surveillance, Epidemiology, and End Results database was queried for all patients diagnosed and treated for cystic RCC and CCRCC between 2001 and 2010. Clinical and pathologic factors were compared using t tests and chi-square tests as appropriate. Kaplan-Meier survival analysis compared CSM differences between cystic RCC and CCRCC. Results A total of 678 patients with cystic RCC and 46,677 with CCRCC were identified. The mean follow-up duration was 52 and 40 months, respectively. When compared with CCRCC patients, those with cystic RCC were younger (mean age 58 vs. 61 y, P
doi_str_mv 10.1016/j.urolonc.2015.07.017
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4843506</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1078143915003609</els_id><sourcerecordid>1735332586</sourcerecordid><originalsourceid>FETCH-LOGICAL-c592t-79146344cd2e57ba28d6c1d57cd8dac49218345158d1cca7bc18d5d3cc913d5d3</originalsourceid><addsrcrecordid>eNqFUk2P0zAQjRCIXRZ-AihHLgme2I6dyyJU8SWtxGHhbLnjaXFJ7WInK8qvx1HLCrhwsUea9958vKmq58BaYNC_2rVzimMM2HYMZMtUy0A9qC5BK950Yugflpgp3YDgw0X1JOcdYyA0wOPqous5DFzCZXW7OubJY50o2LFGGstjE_oQ93aJkqdc21DTjyVHYaoPKW5DzD4XztYmN1LOddzU07yPqc7-Jz2tHm3smOnZ-b-qvrx7-3n1obn59P7j6s1Ng3LopkYNIHouBLqOpFrbTrsewUmFTjuLYuhAcyFBageIVq0RtJOOIw7Al-Cquj7pHub1nhyW7pIdzSH5vU1HE603f2eC_2q28c4ILbhkfRF4eRZI8ftMeTJ7n5c5baA4ZwOKS847qReoPEExxZwTbe7LADOLIWZnzoaYxRDDlCmGFN6LP3u8Z_12oABenwBUNnXnKZmMngKS84lwMi76_5a4_kcBRx882vEbHSnv4pyKt2UakzvDzO1yFctRgGSM92zgvwAA5LaC</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1735332586</pqid></control><display><type>article</type><title>Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Winters, Brian R., M.D ; Gore, John L., M.D., M.S ; Holt, Sarah K., Ph.D ; Harper, Jonathan D., M.D ; Lin, Daniel W., M.D ; Wright, Jonathan L., M.D., M.S</creator><creatorcontrib>Winters, Brian R., M.D ; Gore, John L., M.D., M.S ; Holt, Sarah K., Ph.D ; Harper, Jonathan D., M.D ; Lin, Daniel W., M.D ; Wright, Jonathan L., M.D., M.S</creatorcontrib><description>Abstract Introduction Cystic renal cell carcinoma (cystic RCC) is thought to carry an improved prognosis relative to clear cell RCC (CCRCC); however, this is based on small case series. We used a population-based tumor registry to compare clinicopathologic features and cancer-specific mortality (CSM) of cystic RCC with those of CCRCC. Materials and methods The Surveillance, Epidemiology, and End Results database was queried for all patients diagnosed and treated for cystic RCC and CCRCC between 2001 and 2010. Clinical and pathologic factors were compared using t tests and chi-square tests as appropriate. Kaplan-Meier survival analysis compared CSM differences between cystic RCC and CCRCC. Results A total of 678 patients with cystic RCC and 46,677 with CCRCC were identified. The mean follow-up duration was 52 and 40 months, respectively. When compared with CCRCC patients, those with cystic RCC were younger (mean age 58 vs. 61 y, P &lt;0.001), more commonly black (22% vs. 9%, P &lt;0.001), and female (45% vs. 41%, P = 0.02). Cystic RCCs were more commonly T1a tumors (66% vs. 55%, P &lt;0.001), well differentiated (33% vs. 16%, P &lt;0.001), and smaller (mean size = 3.8 vs. 4.5 cm, P &lt;0.001). Cystic RCC was associated with a reduction in CSM when compared with CCRCC ( P = 0.002). In a subset analysis, this reduction in CSM was seen only for those with T1b/T2 tumors ( P = 0.01) but not for those with T1a RCCs lesions ( P = 0.31). Conclusions We report the largest series of cystic RCC and corroborate the findings of improved CSM when compared with CCRCC for larger tumors; however, no difference was noted in smaller tumors, suggesting that tumor biology becomes more relevant to prognosis with increasing size. These data may suggest a role for active surveillance in appropriately selected patients with small, cystic renal masses.</description><identifier>ISSN: 1078-1439</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2015.07.017</identifier><identifier>PMID: 26319351</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Aged, 80 and over ; Carcinoma, Renal Cell - diagnosis ; Carcinoma, Renal Cell - mortality ; Carcinoma, Renal Cell - pathology ; Clear cell RCC ; Cystic RCC ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Renal cell carcinoma ; Survival ; Survival Analysis ; Urology</subject><ispartof>Urologic oncology, 2015-12, Vol.33 (12), p.505.e9-505.e13</ispartof><rights>Elsevier Inc.</rights><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c592t-79146344cd2e57ba28d6c1d57cd8dac49218345158d1cca7bc18d5d3cc913d5d3</citedby><cites>FETCH-LOGICAL-c592t-79146344cd2e57ba28d6c1d57cd8dac49218345158d1cca7bc18d5d3cc913d5d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26319351$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Winters, Brian R., M.D</creatorcontrib><creatorcontrib>Gore, John L., M.D., M.S</creatorcontrib><creatorcontrib>Holt, Sarah K., Ph.D</creatorcontrib><creatorcontrib>Harper, Jonathan D., M.D</creatorcontrib><creatorcontrib>Lin, Daniel W., M.D</creatorcontrib><creatorcontrib>Wright, Jonathan L., M.D., M.S</creatorcontrib><title>Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>Abstract Introduction Cystic renal cell carcinoma (cystic RCC) is thought to carry an improved prognosis relative to clear cell RCC (CCRCC); however, this is based on small case series. We used a population-based tumor registry to compare clinicopathologic features and cancer-specific mortality (CSM) of cystic RCC with those of CCRCC. Materials and methods The Surveillance, Epidemiology, and End Results database was queried for all patients diagnosed and treated for cystic RCC and CCRCC between 2001 and 2010. Clinical and pathologic factors were compared using t tests and chi-square tests as appropriate. Kaplan-Meier survival analysis compared CSM differences between cystic RCC and CCRCC. Results A total of 678 patients with cystic RCC and 46,677 with CCRCC were identified. The mean follow-up duration was 52 and 40 months, respectively. When compared with CCRCC patients, those with cystic RCC were younger (mean age 58 vs. 61 y, P &lt;0.001), more commonly black (22% vs. 9%, P &lt;0.001), and female (45% vs. 41%, P = 0.02). Cystic RCCs were more commonly T1a tumors (66% vs. 55%, P &lt;0.001), well differentiated (33% vs. 16%, P &lt;0.001), and smaller (mean size = 3.8 vs. 4.5 cm, P &lt;0.001). Cystic RCC was associated with a reduction in CSM when compared with CCRCC ( P = 0.002). In a subset analysis, this reduction in CSM was seen only for those with T1b/T2 tumors ( P = 0.01) but not for those with T1a RCCs lesions ( P = 0.31). Conclusions We report the largest series of cystic RCC and corroborate the findings of improved CSM when compared with CCRCC for larger tumors; however, no difference was noted in smaller tumors, suggesting that tumor biology becomes more relevant to prognosis with increasing size. These data may suggest a role for active surveillance in appropriately selected patients with small, cystic renal masses.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Carcinoma, Renal Cell - diagnosis</subject><subject>Carcinoma, Renal Cell - mortality</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Clear cell RCC</subject><subject>Cystic RCC</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Renal cell carcinoma</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Urology</subject><issn>1078-1439</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqFUk2P0zAQjRCIXRZ-AihHLgme2I6dyyJU8SWtxGHhbLnjaXFJ7WInK8qvx1HLCrhwsUea9958vKmq58BaYNC_2rVzimMM2HYMZMtUy0A9qC5BK950Yugflpgp3YDgw0X1JOcdYyA0wOPqous5DFzCZXW7OubJY50o2LFGGstjE_oQ93aJkqdc21DTjyVHYaoPKW5DzD4XztYmN1LOddzU07yPqc7-Jz2tHm3smOnZ-b-qvrx7-3n1obn59P7j6s1Ng3LopkYNIHouBLqOpFrbTrsewUmFTjuLYuhAcyFBageIVq0RtJOOIw7Al-Cquj7pHub1nhyW7pIdzSH5vU1HE603f2eC_2q28c4ILbhkfRF4eRZI8ftMeTJ7n5c5baA4ZwOKS847qReoPEExxZwTbe7LADOLIWZnzoaYxRDDlCmGFN6LP3u8Z_12oABenwBUNnXnKZmMngKS84lwMi76_5a4_kcBRx882vEbHSnv4pyKt2UakzvDzO1yFctRgGSM92zgvwAA5LaC</recordid><startdate>20151201</startdate><enddate>20151201</enddate><creator>Winters, Brian R., M.D</creator><creator>Gore, John L., M.D., M.S</creator><creator>Holt, Sarah K., Ph.D</creator><creator>Harper, Jonathan D., M.D</creator><creator>Lin, Daniel W., M.D</creator><creator>Wright, Jonathan L., M.D., M.S</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20151201</creationdate><title>Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size</title><author>Winters, Brian R., M.D ; Gore, John L., M.D., M.S ; Holt, Sarah K., Ph.D ; Harper, Jonathan D., M.D ; Lin, Daniel W., M.D ; Wright, Jonathan L., M.D., M.S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c592t-79146344cd2e57ba28d6c1d57cd8dac49218345158d1cca7bc18d5d3cc913d5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Carcinoma, Renal Cell - diagnosis</topic><topic>Carcinoma, Renal Cell - mortality</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Clear cell RCC</topic><topic>Cystic RCC</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Renal cell carcinoma</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Winters, Brian R., M.D</creatorcontrib><creatorcontrib>Gore, John L., M.D., M.S</creatorcontrib><creatorcontrib>Holt, Sarah K., Ph.D</creatorcontrib><creatorcontrib>Harper, Jonathan D., M.D</creatorcontrib><creatorcontrib>Lin, Daniel W., M.D</creatorcontrib><creatorcontrib>Wright, Jonathan L., M.D., M.S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Winters, Brian R., M.D</au><au>Gore, John L., M.D., M.S</au><au>Holt, Sarah K., Ph.D</au><au>Harper, Jonathan D., M.D</au><au>Lin, Daniel W., M.D</au><au>Wright, Jonathan L., M.D., M.S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2015-12-01</date><risdate>2015</risdate><volume>33</volume><issue>12</issue><spage>505.e9</spage><epage>505.e13</epage><pages>505.e9-505.e13</pages><issn>1078-1439</issn><eissn>1873-2496</eissn><abstract>Abstract Introduction Cystic renal cell carcinoma (cystic RCC) is thought to carry an improved prognosis relative to clear cell RCC (CCRCC); however, this is based on small case series. We used a population-based tumor registry to compare clinicopathologic features and cancer-specific mortality (CSM) of cystic RCC with those of CCRCC. Materials and methods The Surveillance, Epidemiology, and End Results database was queried for all patients diagnosed and treated for cystic RCC and CCRCC between 2001 and 2010. Clinical and pathologic factors were compared using t tests and chi-square tests as appropriate. Kaplan-Meier survival analysis compared CSM differences between cystic RCC and CCRCC. Results A total of 678 patients with cystic RCC and 46,677 with CCRCC were identified. The mean follow-up duration was 52 and 40 months, respectively. When compared with CCRCC patients, those with cystic RCC were younger (mean age 58 vs. 61 y, P &lt;0.001), more commonly black (22% vs. 9%, P &lt;0.001), and female (45% vs. 41%, P = 0.02). Cystic RCCs were more commonly T1a tumors (66% vs. 55%, P &lt;0.001), well differentiated (33% vs. 16%, P &lt;0.001), and smaller (mean size = 3.8 vs. 4.5 cm, P &lt;0.001). Cystic RCC was associated with a reduction in CSM when compared with CCRCC ( P = 0.002). In a subset analysis, this reduction in CSM was seen only for those with T1b/T2 tumors ( P = 0.01) but not for those with T1a RCCs lesions ( P = 0.31). Conclusions We report the largest series of cystic RCC and corroborate the findings of improved CSM when compared with CCRCC for larger tumors; however, no difference was noted in smaller tumors, suggesting that tumor biology becomes more relevant to prognosis with increasing size. These data may suggest a role for active surveillance in appropriately selected patients with small, cystic renal masses.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26319351</pmid><doi>10.1016/j.urolonc.2015.07.017</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1078-1439
ispartof Urologic oncology, 2015-12, Vol.33 (12), p.505.e9-505.e13
issn 1078-1439
1873-2496
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4843506
source ScienceDirect Freedom Collection 2022-2024
subjects Aged
Aged, 80 and over
Carcinoma, Renal Cell - diagnosis
Carcinoma, Renal Cell - mortality
Carcinoma, Renal Cell - pathology
Clear cell RCC
Cystic RCC
Female
Humans
Male
Middle Aged
Neoplasm Staging
Prognosis
Renal cell carcinoma
Survival
Survival Analysis
Urology
title Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T08%3A39%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cystic%20renal%20cell%20carcinoma%20carries%20an%20excellent%20prognosis%20regardless%20of%20tumor%20size&rft.jtitle=Urologic%20oncology&rft.au=Winters,%20Brian%20R.,%20M.D&rft.date=2015-12-01&rft.volume=33&rft.issue=12&rft.spage=505.e9&rft.epage=505.e13&rft.pages=505.e9-505.e13&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2015.07.017&rft_dat=%3Cproquest_pubme%3E1735332586%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c592t-79146344cd2e57ba28d6c1d57cd8dac49218345158d1cca7bc18d5d3cc913d5d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1735332586&rft_id=info:pmid/26319351&rfr_iscdi=true